Herbal formula PM012 induces neuroprotection in stroke brain

PLoS One. 2023 Feb 22;18(2):e0281421. doi: 10.1371/journal.pone.0281421. eCollection 2023.

Abstract

Stroke is a major cause of long-term disability world-wide. Limited pharmacological therapy has been used in stroke patients. Previous studies indicated that herb formula PM012 is neuroprotective against neurotoxin trimethyltin in rat brain, and improved learning and memory in animal models of Alzheimer's disease. Its action in stroke has not been reported. This study aims to determine PM012-mediated neural protection in cellular and animal models of stroke. Glutamate-mediated neuronal loss and apoptosis were examined in rat primary cortical neuronal cultures. Cultured cells were overexpressed with a Ca++ probe (gCaMP5) by AAV1 and were used to examine Ca++ influx (Ca++i). Adult rats received PM012 before transient middle cerebral artery occlusion (MCAo). Brain tissues were collected for infarction and qRTPCR analysis. In rat primary cortical neuronal cultures, PM012 significantly antagonized glutamate-mediated TUNEL and neuronal loss, as well as NMDA-mediated Ca++i. PM012 significantly reduced brain infarction and improved locomotor activity in stroke rats. PM012 attenuated the expression of IBA1, IL6, and CD86, while upregulated CD206 in the infarcted cortex. ATF6, Bip, CHOP, IRE1, and PERK were significantly down-regulated by PM012. Using HPLC, two potential bioactive molecules, paeoniflorin and 5-hydroxymethylfurfural, were identified in the PM012 extract. Taken together, our data suggest that PM012 is neuroprotective against stroke. The mechanisms of action involve inhibition of Ca++i, inflammation, and apoptosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brain / metabolism
  • Disease Models, Animal
  • Glutamates
  • Infarction, Middle Cerebral Artery / complications
  • Neuroprotection
  • Neuroprotective Agents* / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Stroke* / etiology

Substances

  • Neuroprotective Agents
  • Glutamates

Grants and funding

This study was supported in part by Mediforum Co., Ltd., Seoul, Republic of Korea (C10-020), Ministry of Science and Technology, Taiwan (MOST 110-2320-B-400-007), Ministry of Health and Welfare, Taiwan (CS-111-GP-02).